NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's clinical study and subsequent strategic decisions [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Intellia, with a deadline of April 14, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Company Developments - Intellia announced a strategic shift on January 9, 2025, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing the development of NTLA-3001, leading to a workforce reduction of approximately 27% [5]. - The company expects to incur charges of around $8 million in the first quarter of 2025 due to this restructuring [5]. Group 3: Market Reaction - Following the announcement of the strategic changes, Intellia's stock price fell by $1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].